Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy

NCT ID: NCT01615250

Last Updated: 2012-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized study of efficiency and safety of intramyocardial implantation of peripheral mononuclear cells with high concentration of CD34+ stem cells in patients with myocardial ischemia after preparatory course of shock - wave therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard therapy

Treatment with standard therapy. Cardiospec shock-wave therapy

Group Type NO_INTERVENTION

No interventions assigned to this group

Stem cells

Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.

Group Type ACTIVE_COMPARATOR

Intramyocardial implantation of stem cells

Intervention Type BIOLOGICAL

Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intramyocardial implantation of stem cells

Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with ischemic cardiomyopaty and HF II-IV NYHA class
* MI more than 6 months before the study
* LVEF less than 35%
* Absence effect of coronary revascularization during 6 months
* Optimal pharmacological therapy no less than 8 weeks
* Heart transplantation is contraindicated
* Patients with implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D)
* Patients giving informed consent

Exclusion Criteria

* Acute coronary syndrome
* Coronary revascularization less than 6 months
* Patients requiring surgical correction of post-MI aneurism
* LV wall thickness less than 5 mm in site of possible injection
* Patients with CRT implanted within 3 month before cells injection
* Clinically significant associated diseases
* Active oncology desiase
* Pregnancy
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Odessa National Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Iurii Kozlov

Dr., PhD Iurii I Karpenko

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Iurii I Karpenko, Dr, PhD

Role: PRINCIPAL_INVESTIGATOR

Odessa National Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Odessa Regional Clinical Hospital

Odesa, , Ukraine

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ukraine

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Iurii I Karpenko, Dr, PhD

Role: CONTACT

+38048750113 ext. +38048750113

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Iurii I Karpenko, Dr, PhD

Role: primary

+380487500115 ext. +380487500115

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ISCIC-2012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Stem Cell Study for Patients With Heart Disease
NCT00221182 TERMINATED PHASE1/PHASE2
Stem Cell in Acute Myocardial Infarction
NCT04340609 COMPLETED PHASE1/PHASE2